Metagenomi, Inc. (NASDAQ:MGX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Metagenomi, Inc. (NASDAQ:MGX) have been given a consensus rating of “Moderate Buy” by the seven analysts that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $16.67.

A number of equities analysts have commented on the stock. Chardan Capital reiterated a “buy” rating and issued a $15.00 price objective on shares of Metagenomi in a report on Wednesday, November 20th. HC Wainwright lifted their target price on Metagenomi from $7.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, December 10th.

Hedge Funds Weigh In On Metagenomi

Institutional investors have recently modified their holdings of the company. Geode Capital Management LLC boosted its position in Metagenomi by 105.8% during the 3rd quarter. Geode Capital Management LLC now owns 338,031 shares of the company’s stock worth $734,000 after acquiring an additional 173,796 shares during the period. Jacobs Levy Equity Management Inc. lifted its holdings in Metagenomi by 209.4% in the third quarter. Jacobs Levy Equity Management Inc. now owns 136,624 shares of the company’s stock worth $296,000 after purchasing an additional 92,468 shares during the period. Novo Holdings A S grew its position in Metagenomi by 3.5% in the 2nd quarter. Novo Holdings A S now owns 1,800,000 shares of the company’s stock valued at $7,344,000 after buying an additional 60,825 shares in the last quarter. Verition Fund Management LLC acquired a new position in Metagenomi during the 3rd quarter valued at about $82,000. Finally, Green Alpha Advisors LLC acquired a new position in Metagenomi during the 3rd quarter valued at about $69,000.

Metagenomi Price Performance

NASDAQ:MGX opened at $3.74 on Monday. Metagenomi has a 12 month low of $1.61 and a 12 month high of $12.74. The business’s 50-day moving average is $2.50 and its two-hundred day moving average is $3.04.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.